Emergency Care Clinic, Haukeland University Hospital , Bergen , Norway.
Department of Heart Disease, Haukeland University Hospital , Bergen , Norway.
Scand Cardiovasc J. 2019 Oct;53(5):280-285. doi: 10.1080/14017431.2019.1634280. Epub 2019 Jul 1.
The main aim of the Aiming toWards Evidence baSed inTerpretation of Cardiac biOmarkers in patients pResenting with chest pain (WESTCOR-study) (Clinical Trials number NCT02620202) is to improve diagnostic pathways for patients presenting to the Emergency department (ED) with acute chest pain. The WESTCOR-study is a two center, cross-sectional and prospective observational study recruiting unselected patients presenting to the ED with suspected non-ST elevation acute coronary syndrome (NSTE-ACS). Patient inclusion started September 2015 and we plan to include 2250 patients, finishing in 2019. The final diagnosis will be adjudicated by two independent cardiologists based on all available information including serial high sensitivity cardiac troponin measurements, coronary angiography, coronary CT angiography and echocardiography. The study includes one derivation cohort ( = 985) that will be used to develop rule out/rule in algorithms for NSTEMI and NSTE-ACS (if possible) using novel troponin assays, and to validate established NSTEMI algorithms, with and without clinical scoring systems. The study further includes one subcohort ( = 500) where all patients are examined with coronary CT angiography independent of biomarker status, aiming to assess the associations between biomarkers and the extent and severity of coronary atherosclerosis. Finally, an external validation cohort ( = 750) will be included at Stavanger University Hospital. Prospective studies will be based on the merged cohorts. The WESTCOR study will provide new diagnostic algorithms for early inclusion and exclusion of NSTE-ACS and insights in the associations between cardiovascular biomarkers, CT-angiographic findings and short and long-term clinical outcomes.
旨在基于证据的心脏生物标志物在胸痛患者中的解释(WESTCOR 研究)(临床试验编号 NCT02620202)的主要目的是改善因急性胸痛就诊于急诊(ED)的患者的诊断途径。WESTCOR 研究是一项两中心、横断面和前瞻性观察研究,招募了因疑似非 ST 段抬高急性冠脉综合征(NSTE-ACS)而就诊于 ED 的非选择性患者。患者入选于 2015 年 9 月开始,我们计划纳入 2250 例患者,预计于 2019 年完成。最终诊断将由两位独立的心脏病专家根据所有可用信息(包括连续的高敏肌钙蛋白测量值、冠状动脉造影、冠状动脉 CT 血管造影和超声心动图)进行裁定。该研究包括一个推导队列( = 985),该队列将用于使用新型肌钙蛋白检测开发 NSTEMI 和 NSTE-ACS 的排除/纳入算法(如果可能),并验证现有的 NSTEMI 算法,包括和不包括临床评分系统。该研究还包括一个亚队列( = 500),其中所有患者都将接受独立于生物标志物状态的冠状动脉 CT 血管造影检查,旨在评估生物标志物与冠状动脉粥样硬化程度和严重程度之间的关联。最后,在斯塔万格大学医院将纳入一个外部验证队列( = 750)。前瞻性研究将基于合并队列进行。WESTCOR 研究将为早期纳入和排除 NSTE-ACS 提供新的诊断算法,并深入了解心血管生物标志物、CT 血管造影结果与短期和长期临床结局之间的关联。